Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2940094 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| LY2940094 | EXPERIMENTAL | 40 mg LY2940094 oral tablet, QD for 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Identically matched placebo oral tablet, QD for 8 weeks |
| Cohort 1: 40 milligram (mg) LY2940094 | EXPERIMENTAL | 40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered). If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration \[tmax\] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts. |
| Cohort 2: 10 mg LY2940094 | EXPERIMENTAL | The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only. If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts. |
| Cohort 3: 4 mg LY2940094 | EXPERIMENTAL | The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only. If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts. |
| Cohort 4: 20 mg LY2940094 | EXPERIMENTAL | The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only. If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts. |
| LY2940094 - single dose | EXPERIMENTAL | Single oral dose of 2-800 milligram (mg) LY2940094 |
| LY2940094 - multiple dose | EXPERIMENTAL | Daily oral dose of 2-200 mg LY2940094 for 14 days |
| Name | Type | Description |
|---|---|---|
| LY2940094 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Present with alcohol dependence (AD) defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR 303.9) * Must have 3 to 6 heavy drinking days per week as assessed by the Timeline Follow Back (TLFB) scale at screening and base...
LY2940094 is an investigational small molecule being studied for major depressive disorder, depression, and alcoholism. It has been evaluated in Phase 2 clinical trials for major depressive disorder and alcohol dependency. The drug is not approved and remains in clinical development.
LY2940094 is being developed by Neumora Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker NMRA. The drug has completed clinical trials in Canada and the United States.
LY2940094 has completed Phase 2 clinical trials. It is an investigational drug and has not received FDA approval. The development program includes completed Phase 1 and Phase 2 studies in major depressive disorder, depression, and alcoholism.
LY2940094 has completed four clinical trials. These include NCT01263236 and NCT01404091, Phase 1 studies in healthy subjects, and NCT01724112 and NCT01798303, Phase 2 studies in major depressive disorder and alcohol dependency. All trials are completed.
LY2940094 is the primary name for this investigational compound. No alternative names have been established in the clinical trial data. The drug is identified by this designation across all registered studies.